By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Vallongatan 1

Uppsala    SE-752 28  Sweden
Phone: 46-18-50-54-40 Fax: 46-18-51-08-73



Company News
Oasmia Reports Positive Results From Study On Weekly Administration Of Apealea (Paclical) 12/22/2016 10:10:22 AM
Oasmia In Discussions Concerning Acquisition Of Novel Cancer Project 10/24/2016 7:50:08 AM
Oasmia Enters Into Collaboration Agreement For Novel Cancer Project 10/24/2016 7:45:32 AM
Sales Focus For Oasmia 6/8/2016 10:54:37 AM
Oasmia Touts Positive Paclical/Apealea Phase III Data; NDA Being Readied for U.S. 4/27/2016 7:09:38 AM
Oasmia Reports Positive Clinical Study Results For Proprietary XR17 Nanotechnology 4/5/2016 1:37:28 PM
Oasmia Announces Enrollment Of First Patient In Clinical Study With Docecal, A Novel Formulation Of Docetaxel 3/30/2016 9:09:52 AM
Oasmia: Interviewed By NyhetsbyrÄn Direkt 3/24/2016 10:07:45 AM
Oasmia Release: OASM Advances Global Commercialization Efforts For All Products 2/25/2016 9:02:27 AM
Oasmia Has Submitted A Marketing Authorization Application To The European Medicines Agency For Its Lead Cancer Product Apealea (Paclical) 2/8/2016 6:18:44 AM